The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Type I Interferon in Chronic Virus Infection and Cancer
Open accessAbstract
Type I interferons (IFN-Is) are emerging as key drivers of inflammation and immunosuppression in chronic infection. Control of these infections requires IFN-I signaling; however, prolonged IFN-I signaling can lead to immune dysfunction. IFN-Is are also emerging as double-edged swords in cancer, providing necessary inflammatory signals, while initiating feedback suppression in both immune and cancer cells. Here, we review the proinflammatory and suppressive mechanisms potentiated by IFN-Is during chronic virus infections and discuss the similar, newly emerging dichotomy in cancer. We then discuss how this understanding is leading to new therapeutic concepts and immunotherapy combinations. We propose that, by modulating the immune response at its foundation, it may be possible to widely reshape immunity to control these chronic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Regulatory B Cells: Origin, Phenotype, and Function
Rosser, E. C., & Mauri, C. (2015) · Immunity · doi:10.1016/j.immuni.2015.04.005 · Cited by 1,455
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Utzschneider, D. T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D. P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.021 · Cited by 1,085
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Immunomodulatory functions of type I interferons
González-Navajas, J. M., Lee, J., David, M., & Raz, E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3133 · Cited by 1,011
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J., & Murali-Krishna, K. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050821 · Cited by 965
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L., Silvestri, G., Freeman, G. J., et al. (2009) · Nature · doi:10.1038/nature07662 · Cited by 771
Persistent LCMV infection is controlled by blockade of type I interferon signaling
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science · doi:10.1126/science.1235214 · Cited by 755
Blockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709
Self-citationFollicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X., et al. (2016) · Nature · doi:10.1038/nature19317 · Cited by 677
Interferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness
Wu, T., Ji, Y., Moseman, E. A., Xu, H. C., Manglani, M., Kirby, M., Anderson, S. M., Handon, R., Kenyon, E., Elkahloun, A., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aai8593 · Cited by 627
Kroeger, D. R., Milne, K., & Nelson, B. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2762 · Cited by 610
Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia
Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.-L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370402 · Cited by 543
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
Bidwell, B. N., Slaney, C. Y., Withana, N. P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N. E., Samarajiwa, S. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2830 · Cited by 487
Jacquelin, B., Mayau, V., Targat, B., Liovat, A.-S., Kunkel, D., Petitjean, G., Dillies, M.-A., Roques, P., Butor, C., Silvestri, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40093 · Cited by 481
Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression
Sandler, N. G., Bosinger, S. E., Estes, J. D., Zhu, R. T. R., Tharp, G. K., Boritz, E., Levin, D., Wijeyesinghe, S., Makamdop, K. N., del Prete, G. Q., et al. (2014) · Nature · doi:10.1038/nature13554 · Cited by 461
Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer
Treilleux, I., Blay, J.-Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J.-P., Bremond, A., Goddard, S., Pin, J.-J., Barthelemy-Dubois, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0684 · Cited by 460
Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.-L., Coltescu, C., Heathcote, J., Edwards, A. M., & McGilvray, I. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.059 · Cited by 453
Immune activation and HIV persistence: implications for curative approaches to HIV infection
Klatt, N. R., Chomont, N., Douek, D. C., & Deeks, S. G. (2013) · Immunological Reviews · doi:10.1111/imr.12065 · Cited by 435
Phenotypic properties of transmitted founder HIV-1
Parrish, N. F., Gao, F., Li, H., Giorgi, E. E., Barbian, H. J., Parrish, E. H., Zajic, L., Iyer, S. S., Decker, J. M., Kumar, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304288110 · Cited by 422
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
Expansion of HIV-specific T follicular helper cells in chronic HIV infection
Lindqvist, M., van Lunzen, J., Soghoian, D. Z., Kuhl, B. D., Ranasinghe, S., Kranias, G., Flanders, M. D., Cutler, S., Yudanin, N., Muller, M. I., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64314 · Cited by 418
Bosinger, S. E., Li, Q., Gordon, S. N., Klatt, N. R., Duan, L., Xu, L., Francella, N., Sidahmed, A., Smith, A. J., Cramer, E. M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40115 · Cited by 409
Mandelli, F., Avvisati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauta, V. M., Marmont, F., Petrucci, M. T., Tribalto, M., Vegna, M. L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005173222005 · Cited by 382
Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., Renaudineau, S., Poyet, G., Labidi-Galy, S. I., Goddard-Leon, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3468 · Cited by 345
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343
Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., & Honjo, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003208 · Cited by 342
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A. G., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87624 · Cited by 336
Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells
Fahey, L. M., Wilson, E. B., Elsaesser, H., Fistonich, C. D., McGavern, D. B., & Brooks, D. G. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101773 · Cited by 320
Self-citationCD4 T follicular helper cell dynamics during SIV infection
Petrovas, C., Yamamoto, T., Gerner, M. Y., Boswell, K. L., Wloka, K., Smith, E. C., Ambrozak, D. R., Sandler, N. G., Timmer, K. J., Sun, X., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63039 · Cited by 317
Vermi, W., Bonecchi, R., Facchetti, F., Bianchi, D., Sozzani, S., Festa, S., Berenzi, A., Cella, M., & Colonna, M. (2003) · The Journal of Pathology · doi:10.1002/path.1344 · Cited by 295
Boasso, A., Herbeuval, J.-P., Hardy, A. W., Anderson, S. A., Dolan, M. J., Fuchs, D., & Shearer, G. M. (2007) · Blood · doi:10.1182/blood-2006-07-034785 · Cited by 288
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Yang, X., Zhang, X., Fu, M. L., Weichselbaum, R. R., Gajewski, T. F., Guo, Y., & Fu, Y.-X. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.004 · Cited by 269
Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1
de Weerd, N. A., Vivian, J. P., Nguyen, T. K., Mangan, N. E., Gould, J. A., Braniff, S.-J., Zaker-Tabrizi, L., Fung, K. Y., Forster, S. C., Beddoe, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2667 · Cited by 264
Yamada, T., Horimoto, H., Kameyama, T., Hayakawa, S., Yamato, H., Dazai, M., Takada, A., Kida, H., Bott, D., Zhou, A. C., et al. (2016) · Nature Immunology · doi:10.1038/ni.3422 · Cited by 251
Katlinski, K. V., Gui, J., Katlinskaya, Y. V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C. J., Beiting, D. P., Girondo, M. A., Peck, A. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.004 · Cited by 248
Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma
Castino, G. F., Cortese, N., Capretti, G., Serio, S., Di Caro, G., Mineri, R., Magrini, E., Grizzi, F., Cappello, P., Novelli, F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1085147 · Cited by 246
Chawla‐Sarkar, M., Leaman, D. W., & Borden, E. C. (2001) · PubMed · Cited by 245
Buisseret, L., Garaud, S., de Wind, A., Van den Eynden, G., Boisson, A., Solinas, C., Gu-Trantien, C., Naveaux, C., Lodewyckx, J.-N., Duvillier, H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1257452 · Cited by 237
Mueller, S. N., Matloubian, M., Clemens, D. M., Sharpe, A. H., Freeman, G. J., Gangappa, S., Larsen, C. P., & Ahmed, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702579104 · Cited by 234
Role of regulatory T cells during virus infection
Veiga‐Parga, T., Sehrawat, S., & Rouse, B. T. (2013) · Immunological Reviews · doi:10.1111/imr.12085 · Cited by 232
Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity
Xu, H. C., Grusdat, M., Pandyra, A. A., Polz, R., Huang, J., Sharma, P., Deenen, R., Köhrer, K., Rahbar, R., Diefenbach, A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.004 · Cited by 231
Ray, J. P., Marshall, H. D., Laidlaw, B. J., Staron, M. M., Kaech, S. M., & Craft, J. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.005 · Cited by 230
Type I Interferons Protect T Cells against NK Cell Attack Mediated by the Activating Receptor NCR1
Crouse, J., Bedenikovic, G., Wiesel, M., Ibberson, M., Xenarios, I., Von Laer, D., Kalinke, U., Vivier, E., Jonjic, S., & Oxenius, A. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.003 · Cited by 229
Penaloza-MacMaster, P., Kamphorst, A. O., Wieland, A., Araki, K., Iyer, S. S., West, E. E., O’Mara, L., Yang, S., Konieczny, B. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132577 · Cited by 213
Getts, D. R., Turley, D. M., Smith, C. E., Harp, C. T., McCarthy, D., Feeney, E. M., Getts, M. T., Martin, A. J., Luo, X., Terry, R. L., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004175 · Cited by 198
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase
Ravishankar, B., Liu, H., Shinde, R., Chandler, P., Baban, B., Tanaka, M., Munn, D. H., Mellor, A. L., Karlsson, M. C. I., & McGaha, T. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117736109 · Cited by 198
Self-citationThompson, L. J., Kolumam, G. A., Thomas, S., & Murali-Krishna, K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1746 · Cited by 197
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity
McGaha, T. L., Huang, L., Lemos, H., Metz, R., Mautino, M., Prendergast, G. C., & Mellor, A. L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01149.x · Cited by 197
Self-citationRelative resistance of HIV-1 founder viruses to control by interferon-alpha
Fenton-May, A. E., Dibben, O., Emmerich, T., Ding, H., Pfafferott, K., Aasa-Chapman, M. M., Pellegrino, P., Williams, I., Cohen, M. S., Gao, F., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-146 · Cited by 197
Azzoni, L., Foulkes, A. S., Papasavvas, E., Mexas, A. M., Lynn, K. M., Mounzer, K., Tebas, P., Jacobson, J. M., Frank, I., Busch, M. P., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis663 · Cited by 189
Targeting type I interferon–mediated activation restores immune function in chronic HIV infection
Zhen, A., Rezek, V., Youn, C., Lam, B., Chang, N., Rick, J., Carrillo, M., Martin, H., Kasparian, S., Syed, P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci89488 · Cited by 187
Self-citationThe Role of IL-10 in Regulating Immunity to Persistent Viral Infections
Wilson, E. B., & Brooks, D. G. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_96 · Cited by 176
Self-citationBlocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs
Cheng, L., Ma, J., Li, J., Li, D., Li, G., Li, F., Zhang, Q., Yu, H., Yasui, F., Ye, C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci90745 · Cited by 176
Sharma, M. D., Hou, D.-Y., Baban, B., Koni, P. A., He, Y., Chandler, P. R., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2010) · Immunity · doi:10.1016/j.immuni.2010.11.022 · Cited by 175
Hall, M., Bates, S., & Peters, G. (1995) · PubMed · Cited by 174
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
Stewart, C. A., Metheny, H., Iida, N., Smith, L., Hanson, M., Steinhagen, F., Leighty, R. M., Roers, A., Karp, C. L., Müller, W., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65180 · Cited by 173
Wang, Y., Swiecki, M., Cella, M., Alber, G., Schreiber, R. D., Gilfillan, S., & Colonna, M. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.05.003 · Cited by 172
The PTEN pathway in T regs is a critical driver of the suppressive tumor microenvironment
Sharma, M. D., Shinde, R., McGaha, T. L., Huang, L., Holmgaard, R. B., Wolchok, J. D., Mautino, M. R., Celis, E., Sharpe, A. H., Francisco, L. M., et al. (2015) · Science Advances · doi:10.1126/sciadv.1500845 · Cited by 171
Self-citationResistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
Foster, T. L., Wilson, H., Iyer, S. S., Coss, K., Doores, K., Smith, S., Kellam, P., Finzi, A., Borrow, P., Hahn, B. H., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.08.006 · Cited by 171
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
Heim, M. H. (2013) · Nature reviews. Immunology · doi:10.1038/nri3463 · Cited by 165
Srivastava, S., Koch, M. A., Pepper, M., & Campbell, D. J. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131556 · Cited by 162
A Multiple-Dose Phase I Trial of Recombinant Leukocyte A Interferon in Cancer Patients
Sherwin, S. A., Knost, J. A., Fein, S., Abrams, P. G., Foon, K. A., Ochs, J. J., Schoenberger, C., Maluish, A. E., & Oldham, R. K. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03330190025025 · Cited by 161
Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes
Ng, C. T., Mendoza, J. L., García, K. C., & Oldstone, M. B. A. (2016) · Cell · doi:10.1016/j.cell.2015.12.027 · Cited by 143
Sangfelt, O., Erickson, S., Castro, J., Heiden, T., Gustafsson, A., Einhorn, S., & Grandér, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202609 · Cited by 139
Ding, Z., Lu, X., Yu, M., Lemos, H. D. P., Huang, L., Chandler, P., Liu, K., Walters, M. J., Krasinski, A., Mack, M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3596 · Cited by 136
Huang, L., Li, L., Lemos, H. D. P., Chandler, P., Pacholczyk, G. A., Baban, B., Barber, G. N., Hayakawa, Y., McGaha, T. L., Ravishankar, B., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301419 · Cited by 128
Self-citationAlberts, D. S., Marth, C., Alvarez, R. D., Johnson, G. A., Bidziński, M., Kardatzke, D. R., Bradford, W. Z., Loutit, J. S., Kirn, D. H., Clouser, M. C., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.005 · Cited by 127
Zúñiga, E. I., Liou, L., Mack, L. A., Mendoza, M., & Oldstone, M. B. A. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.08.016 · Cited by 125
Inflammatory monocytes hinder antiviral B cell responses
Sammicheli, S., Kuka, M., Lucia, P. D., de Oya, N. J., Giovanni, M. D., Fioravanti, J., Cristofani, C., Maganuco, C. G., Fallet, B., Ganzer, L., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aah6789 · Cited by 119
Dai, W., & Gupta, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45453-6 · Cited by 115
Interferon-driven deletion of antiviral B cells at the onset of chronic infection
Fallet, B., Narr, K., Ertuna, Y. I., Remy, M. M., Sommerstein, R., Cornille, K., Kreutzfeldt, M., Pagé, N., Zimmer, G., Geier, F. M., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aah6817 · Cited by 112
Multifaceted Activities of Type I Interferon Are Revealed by a Receptor Antagonist
Levin, D., Schneider, W. M., Hoffmann, H.-H., Yarden, G., Busetto, A. G., Manor, O., Sharma, N., Rice, C. M., & Schreiber, G. (2014) · Science Signaling · doi:10.1126/scisignal.2004998 · Cited by 111
Interferon-α Suppresses cAMP to Disarm Human Regulatory T Cells
Bacher, N., Raker, V., Hofmann, C., Graulich, E., Schwenk, M., Baumgrass, R., Bopp, T., Zechner, U., Merten, L., Becker, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3788 · Cited by 111
Widschwendter, A., Geymayer, S., Welte, T., Daxenbichler, G., Marth, C., & Doppler, W. (2002) · PubMed · Cited by 108
Mansfield, A. S., Heikkilä, P., Vaara, A. T., von Smitten, K., Vakkila, J., & Leidenius, M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-231 · Cited by 108
Osokine, I., Snell, L. M., Cunningham, C. R., Yamada, D. H., Wilson, E. B., Elsaesser, H. J., de la Torre, J. C., & Brooks, D. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401662111 · Cited by 105
Self-citationÖsterborg, A., Björkholm, M., Björeman, M., Brenning, G., Carlson, K. E., Celsing, F., Gahrton, G., Grimfors, G., Gyllenhammar, H., & Hast, R. (1993) · Blood · doi:10.1182/blood.v81.6.1428.1428 · Cited by 104
Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy
Bosinger, S. E., & Utay, N. S. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-014-0244-6 · Cited by 100
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
Speeckaert, R., Vermaelen, K., van Geel, N., Autier, P., Lambert, J., Haspeslagh, M., Gele, M. V., Thielemans, K., Neyns, B., Roche, N. A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.007 · Cited by 100
Snell, L. M., Osokine, I., Yamada, D. H., la Fuente, J. R. O. D., Elsaesser, H. J., & Brooks, D. G. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.065 · Cited by 98
Self-citationMoseman, E. A., Wu, T., de la Torre, J. C., Schwartzberg, P. L., & McGavern, D. B. (2016) · Science Immunology · doi:10.1126/sciimmunol.aah3565 · Cited by 94
Effects of IFN‐α as a signal‐3 cytokine on human naïve and antigen‐experienced CD8+ T cells
Hervás‐Stubbs, S., Riezu‐Boj, J. I., González, I., Mancheño, U., Dubrot, J., Azpilikueta, A., Gabari, I., Palazón, A., Aranguren, A., Ruiz, J., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.201040664 · Cited by 92
Type‐I IFN drives the differentiation of short‐lived effector CD8+ T cells in vivo
Wiesel, M., Crouse, J., Bedenikovic, G., Sutherland, A. P. R., Joller, N., & Oxenius, A. (2011) · European Journal of Immunology · doi:10.1002/eji.201142091 · Cited by 91
Ding, Z., Huang, L., Blazar, B. R., Yagita∥, H., Mellor, A. L., Munn, D. H., & Zhou, G. (2012) · Blood · doi:10.1182/blood-2011-12-398321 · Cited by 88
Tumor-infiltrating B cells and T cells
Nielsen, J. S., & Nelson, B. H. (2012) · OncoImmunology · doi:10.4161/onci.21650 · Cited by 85
Purtha, W. E., Chachu, K. A., Virgin, H. W., & Diamond, M. (2008) · Journal of Virology · doi:10.1128/jvi.01646-08 · Cited by 84
Impaired Antibody Response Causes Persistence of Prototypic T Cell–Contained Virus
Bergthaler, A., Flatz, L., Verschoor, A., Hegazy, A. N., Holdener, M., Fink, K., Eschli, B., Merkler, D., Sommerstein, R., Horváth, E. J., et al. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000080 · Cited by 81
Cunningham, C. R., Champhekar, A. S., Tullius, M. V., Dillon, B. J., Zhen, A., la Fuente, J. R. O. D., Herskovitz, J., Elsaesser, H. J., Snell, L. M., Wilson, E. B., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005356 · Cited by 75
Self-citationMonocyte-Derived Dendritic Cells Perform Hemophagocytosis to Fine-Tune Excessive Immune Responses
Ohyagi, H., Onai, N., Sato, T., Yotsumoto, S., Liu, J., Akiba, H., Yagita∥, H., Atarashi, K., Honda, K., Roers, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.019 · Cited by 74
Ding, Z., Blazar, B. R., Mellor, A. L., Munn, D. H., & Zhou, G. (2010) · Blood · doi:10.1182/blood-2009-11-253336 · Cited by 72
Type I Interferons Induce Apoptosis by Balancing cFLIP and Caspase-8 Independent of Death Ligands
Apelbaum, A., Yarden, G., Warszawski, S., Harari, D., & Schreiber, G. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.01430-12 · Cited by 68
Alberts, D. S., Hannigan, E. V., Liu, P.-Y., Jiang, C. S., Wilczynski, S. P., Copeland, L. J., & Markman, M. M. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.07.117 · Cited by 65
Wilson, E. B., Kidani, Y., Elsaesser, H. J., Barnard, J., Raff, L., Karp, C. L., Bensinger, S. J., & Brooks, D. G. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.03.009 · Cited by 64
Self-citationSuppression of Fcγ-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection
Yamada, D. H., Elsaesser, H. J., Lux, A., Timmerman, J. M., Morrison, S. L., de la Torre, J. C., Nimmerjahn, F., & Brooks, D. G. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.005 · Cited by 63
Self-citationWieland, A., Shashidharamurthy, R., Kamphorst, A. O., Han, J., Aubert, R. D., Choudhury, B., Stowell, S. R., Lee, J., Punkosdy, G. A., Shlomchik, M. J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.009 · Cited by 62
Nice, T. J., Osborne, L. C., Tomov, V. T., Artis, D., Wherry, E. J., & Virgin, H. W. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005684 · Cited by 61
Bernardo, A. R., Cosgaya, J. M., Aranda, A., & Jimenez-Lara, A. M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.5 · Cited by 59
Lee, M. S., Park, C. H., Jeong, Y. H., Kim, Y., & Ha, S. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003478 · Cited by 51
Type I IFN gene delivery suppresses regulatory T cells within tumors
Hashimoto, H., Ueda, R., Narumi, K., Heike, Y., Yoshida, T., & Aoki, K. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.60 · Cited by 50
Ilander, M. M., Kreutzman, A. S., Rohoň, P., Melo, T. P. E., Faber, E., Porkka, K., Vakkila, J., & Mustjoki, S. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087794 · Cited by 41
B Cell–Intrinsic IDO1 Regulates Humoral Immunity to T Cell–Independent Antigens
Shinde, R. S., Shimoda, M., Chaudhary, K., Liu, H., Mohamed, E. T., Bradley, J., Kandala, S., Li, X., Liu, K., & McGaha, T. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402854 · Cited by 41
Self-citationSunshine, J. E., Larsen, B. B., Maust, B. S., Casey, E., Deng, W., Chen, L., Westfall, D. H., Kim, M., Zhao, H. C., Ghorai, S., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01876-15 · Cited by 31
Patients with chronic hepatitis C express a high percentage of CD4+CXCR5+ T follicular helper cells
Feng, J., Hu, X., Guo, H., Sun, X., Wang, J., Xu, L., Jiang, Z., Xu, B., Niu, J., & Jiang, Y. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0568-1 · Cited by 30
Honke, N., Shaabani, N., Merches, K., Gassa, A., Kraft, A. R. M., Ehrhardt, K., Häussinger, D., Löhning, M., Dittmer, U., Hengel, H., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201545765 · Cited by 25
Regulatory T Cells Resist Virus Infection-Induced Apoptosis
Che, J. W., Kraft, A. R. M., Selin, L. K., & Welsh, R. M. (2014) · Journal of Virology · doi:10.1128/jvi.02245-14 · Cited by 17
Who Benefits Most From Adjuvant Interferon Treatment for Melanoma?
Gogas, H. J., Abalı, H., Ascierto, P. A., et al. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31829e883d · Cited by 17
PEG-rIL-10 treatment decreases FoxP3+Tregs despite upregulation of intratumoral IDO
Chan, I. H., Wu, V. H., Bilardello, M., Jorgenson, B., Bal, H., McCauley, S., Vlasselaer, P. V., & Mumm, J. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1197458 · Cited by 14
B-cell abnormalities and impact on antibody response in HIV infection
Noto, A., & Pantaleo, G. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000359 · Cited by 13
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
The JAK-STAT pathway at 30: Much learned, much more to do
Philips, R. L., Wang, Y., Cheon, H., Kanno, Y., Gadina, M., Sartorelli, V., Horvath, C. M., Darnell, J. E., Stark, G. R., & O’Shea, J. J. (2022) · Cell · doi:10.1016/j.cell.2022.09.023 · Cited by 720
Benci, J. L., Johnson, L. R., Choa, R., Xu, Y., Qiu, J., Zhou, Z., Xu, B., Ye, D., Nathanson, K. L., June, C. H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.019 · Cited by 541
Epigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & De Carvalho, D. D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 550
Metadata
- Authors
- Snell, L. M., McGaha, T. L., & Brooks, D. G.
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 38
- Issue
- 8
- Pages
- 542-557
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W2621003511
- Cited by
- 500
- References
- 125
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.